Thus, FTDs have lower levels of the secreted form of the amyloid precursor protein [217], and the combined use of altered NfL values and normal values of β-amyloid 42 allows patients with FTD to be differentiated with good sensitivity and specificity from AD ones or healthy controls [180]. This evidence concerns the gene NEFL and frontotemporal dementia.